2026-11-14 · 2026-11 / week-2
SPCE’s $250M open-market sale agreement may buy runway, but the 31% gap leaves no bounded short
SPCE’s $250M open-market sale agreement may buy runway, but the 31% gap leaves no bounded short
Summary: SPCE was $1.86 at 3:10:46 p.m. ET Nov. 13, down 30.3% from the $2.67 prior close. Q3 free cash flow was -$99.1M, and the 10-Q said planned mitigation did not alleviate substantial doubt. A new open-market sale agreement allows up to $250M gross, but no sales were reported by this cutoff; a separate $12.5M note exchange would issue shares and reduce a future cash payment if completed. Short interest was already 40.17% of provider float at Oct. 30. The reference-only map has no 10% base decline and an adverse rebound above 5%. Reject / no trade.
| Run field | Value |
|---|---|
| Published | November 14, 2026, 04:11 Singapore time |
| Research cutoff | November 14, 2026, 04:11 Singapore time (November 13, 3:11 p.m. ET) |
| Scope | U.S.-listed short opportunities |
| Decision | Reject / no trade |
| Reference | SPCE, $1.86 at 3:10:46 p.m. ET Nov. 13; regular-session finance-feed snapshot about 1 minute old at cutoff. |
Scope and Search Audit
The screen covers U.S.-listed short candidates only. Searches covered fresh financing and debt terms, post-earnings margin and guidance changes, and a deal-driven balance-sheet reset. The prior run’s KLC Q3 screen was not repeated. SPCE appeared once as a July comparison in an MVIS article; its November Q3 results, new sale agreement, and Nov. 13 debt exchange materially change that evidence boundary.
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence freshness | Catalyst window | Positioning | 10/5 status | Tradeability | Main rejection risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SPCE | Short | A new open-market sale agreement up to $250M and a stock-settled note exchange followed a Q3 with a $99.1M FCF loss; shares fell 30.3% in the Nov. 13 session. | Nov. 12 SEC 10-Q and 8-K; Nov. 13 SEC 8-K and 3:10:46 p.m. ET price. | Nov. 17–18 VWAP period and expected Nov. 19 exchange close; January glide-flight test; first commercial flight targeted for early Q2 2027. | Oct. 30 short interest was 40.17% of provider float and 7.57 days to cover; it predates the news. | Reject | NYSE listing and heavy event volume, but current locate, borrow, spread, depth, and exit terms are unknown. | The financing may extend runway, the note exchange reduces a cash obligation, and a crowded short can rebound on flight news. |
| 2 | CDNL | Short | Q3 revenue rose 65.1%, but adjusted EBITDA margin was 4.2%, full-year guidance was withdrawn, and the Hughes Brothers deal was postponed. | Nov. 12 SEC Q3 release and 10-Q; Nov. 13 3:10:11 p.m. ET price. | Future project execution and any renewed acquisition timetable; no new deal date announced. | Oct. 30 short interest was 2.82M shares and 2.54 days to cover. The provider’s displayed float denominator is inconsistent with outstanding shares, so its short-float percentage is unusable. | Reject | About $137M provider market value; current borrow, spread, depth, and exit data unknown. | The shares rose 17.0% on Nov. 13; cash was $335M, issuer-defined net cash debt was -$136.5M, and the discretionary $50M buyback is not a commitment. |
| 3 | HRTX | Short | Q3 net revenue fell 7.8%, with oncology revenue down 22.2%, but substantially all operating assets are under a pending sale. | Nov. 9 issuer Q3 release and asset-sale terms; Nov. 13 3:07:57 p.m. ET price. | CorMedix transaction expected in Q1 2027, subject to HRTX stockholder approval, regulatory clearance, and other conditions. | Oct. 30 short interest was 34.0M shares, 23.21% of provider float and 19.54 days to cover; stale and unusually high. | Reject | About $62M provider market value; transaction is binary and current borrow and exit terms are unknown. | HRTX remains public and would receive $145M cash, 14.58M CRMD shares, and contingent earn-outs and royalties before debt repayment and other claims. |
| Control | SPY | Short | Broad-market control; the ETF does not isolate SPCE’s financing and flight-test risk. | Nov. 13 3:10:40 p.m. ET price. | None identified for a standalone short. | Index exposure does not establish an issuer-specific short catalyst. | No setup | Liquid benchmark; no differentiated short mechanism. | A broad-market move does not bound SPCE’s financing or operational outcomes. |
Selected research screen: SPCE ranks first for information value, not as the best executable short. Its funding and share-settlement terms now sit beside a fresh going-concern disclosure and high, stale short interest. That disagreement is material, but the price reaction and financing flexibility leave the downside unbounded.
Why this one now: The Q3 filing is explicit about cash use and substantial doubt, while the Nov. 12–13 financing actions are real but not all completed. The stock is already down roughly 30% in the first post-result session. A short thesis can be directionally right about dilution and still lose on the cash runway, note exchange, astronaut bookings, or flight-test news.
What should surprise the reader: The prior $300M ATM had sold $295.8M gross by September, yet the company then signed a separate open-market sale agreement for up to $250M gross. At $1.86, selling the full amount at a constant price would mean about 134.4M shares, or 88.6% of the 151.68M shares outstanding on Nov. 5. That is a mechanical sensitivity, not a sales forecast; the agreement does not require the company to sell the full amount.
Why This Is the Best Opportunity Right Now
SPCE has the clearest fresh financing bridge. The 10-Q reports $0.4M of Q3 revenue, a $99.1M Q3 free-cash-flow loss, and a going-concern conclusion. The following filings add sale capacity, a stock exchange for $12.5M of 2027 notes, and an amendment to asset-sale proceeds under the 2028 note indenture.
CDNL’s margins and guidance deteriorated, but cash and the share-price response complicate the short. HRTX’s revenue mix weakened, but the pending asset sale puts cash, CRMD shares, debt repayment, and approval conditions between operations and the residual equity. Neither offers a cleaner current short path than SPCE, and none passes 10/5.
Why This Can Move More Than 5% Soon
The reference is $1.86 after a 30.3% session decline. The new note exchange is expected to close around Nov. 19 after a two-day VWAP observation period beginning Nov. 17. A January glide-flight test and a first commercial flight targeted for early Q2 2027 create large positive and negative event paths. The Oct. 30 short-interest reading was 40.17% of provider float, enough to make the rebound risk consequential, though it predates the Q3 release and financing news.
10/5 Asymmetry Gate
The highest-probability reference case is stabilization at $1.86, a 0% short return. The observed session low of $1.815 is only 2.4% lower. A retrace to the $2.67 prior close is a 43.5% adverse rise for a short. Neither price marker is fair value or a ceiling. No operating, capital-structure, or valuation model supports a 10% base decline while bounding a credible adverse move to 5%. Reject before execution and costs.
The Setup
Virgin Galactic is still pre-commercial. Q3 revenue was $0.427M, mostly astronaut access fees and an event. Net loss was $58.8M. Adjusted EBITDA was -$46.8M. Net cash used in operations was $58.0M and capital expenditures were $41.1M, producing issuer-defined free cash flow of -$99.1M. Q4 free cash flow guidance was -$80M to -$90M.
At Sept. 30, the balance sheet reported $144.0M of cash and cash equivalents, $9.0M of marketable securities, and $31.3M of restricted cash. The restricted balance consists primarily of astronaut deposits unavailable for general use until the condition of carriage is signed or deposits are refunded. Unrestricted cash and securities therefore total about $153.0M on that date. The Q3 10-Q concluded that its plans did not alleviate substantial doubt over the next twelve months; the filing did not treat prospective capital-market proceeds or future spaceflight revenue as probable. That conclusion predates the Nov. 12–13 financing actions, none of whose contemplated proceeds had been reported as received by this cutoff.
At Sept. 30, contractual debt principal was about $192.3M: $172.0M of 9.80% First Lien Notes due 2028, $17.9M of 2.50% convertible notes due February 2027, and a small commercial loan. After May and June redemptions, no mandatory principal payment on the First Lien Notes was due before March 2028. On Nov. 13, a holder agreed to exchange $12.5M of the 2027 notes for shares; if completed, the remaining note principal falls to $5.4M. It does not bring cash into the company and the share count depends on the Nov. 16 close and Nov. 17–18 VWAPs.
The new open-market sale agreement allows up to $250M gross in sales from time to time. The issuer says at least 35% of net cash proceeds must be used to redeem First Lien Notes under the indenture. Actual sale amounts, sale prices, and net proceeds are unknown. As of Sept. 30, the earlier $300M 2024 ATM had already sold $295.8M gross. The November filing disclosed a separate open-market sale agreement. The filings reviewed report no sale under it by this cutoff.
The Nov. 13 indenture amendment permits certain asset sales without triggering the indenture’s prior sale-proceeds redemption rule. For a qualifying sale before July 30, 2027, the company must redeem principal equal to 80% of net cash proceeds above $5M. It may pay that redemption in cash or, at its option, up to 2,230,425 shares. No specific asset sale or proceeds were identified in the filing.
The Market Price
The finance feed showed SPCE at $1.86 at 3:10:46 p.m. ET Nov. 13, down $0.81 (30.3%) from its $2.67 prior close, with a $1.815–$2.60 session range, 6.64M shares of volume, and about $282.0M market capitalization. The SEC 10-Q reported 151,681,991 common shares outstanding as of Nov. 5; multiplying that denominator by $1.86 gives about $282.1M. These are close but not identical provider values. ChartExchange showed a $2.69 Nov. 12 close; the scenario map uses the $2.67 finance-feed basis, without averaging. The quote is a reference, not an executable entry; it was about 1 minute old at the 3:11 p.m. ET cutoff.
At $1.86, the $250M gross sale limit equals about 134.4M shares if all shares were sold at this price, or 88.6% of the 151.68M shares outstanding. This assumes a constant price and full use of the facility; it is not a forecast. Price impact, commissions, the required debt redemption, and future sale prices are excluded.
The Mispricing
Price: A 30.3% first-session decline followed Q3 results and two financing disclosures. That move shows a sharp repricing, but it does not measure the remaining downside. At about $281M of equity value against Q3 revenue of $0.4M and $99.1M of negative FCF, a revenue multiple is not an informative valuation anchor.
Reality: Q3 cash use, minimal current revenue, and the filed substantial-doubt conclusion support the bear case. The 2024 ATM was almost exhausted by September and the company had issued shares to redeem notes. But the new $250M gross sale capacity is financing access rather than cash already raised; its use may fund operations and reduce secured debt. The 2027 note exchange also avoids a future cash repayment, at the cost of more shares.
Positioning: FINRA data compiled by ChartExchange show 40,227,126 SPCE shares short, equal to 40.17% of provider float and 7.57 days to cover at the Oct. 30 settlement. The number predates the Nov. 12–13 news and gap. Current positions, borrow cost, recalls, and lender supply are unknown. High short interest is not proof of a squeeze, but it raises the cost of assuming a rebound is capped.
Inference: The market may be discounting the cost and dilution needed to reach commercial service. It may also be discounting the chance that the newly disclosed financing and note exchange fund the company through flight tests. The critical unknown is not whether further issuance is possible; it is how much cash will be raised, at what price, and whether it converts into validated flight operations before the runway narrows.
The Positioning
Reported short interest is large but stale. The Oct. 30 settlement preceded the earnings release and the 30.3% down session. No current borrow fee, locate, recall condition, lender concentration, or post-event short-covering data were verified. The provider’s 7.57 days to cover uses its historical volume basis, not the Nov. 13 event volume.
The Catalyst
- Note exchange: Nov. 16 closing price sets the VWAP floor and cap; the two observation days are Nov. 17–18. Closing is expected around Nov. 19, subject to customary conditions. Verify the actual share count and remaining note principal.
- Open-market sale use: Monitor filings for shares sold, gross and net proceeds, average price, commissions, and the amount applied to First Lien Notes. Capacity is not cash and no sales schedule was announced.
- Vehicle test: The Q3 release targets the first glide flight with Apeiron in January 2027. A delay, test issue, or schedule confirmation could move expectations sharply.
- Commercial service: The company targets the first commercial flight for early Q2 2027. Verify a completed flight and cash conversion; announcements and reservations are not recognized flight revenue.
- Asset sales: No sale is announced. If one occurs by July 30, 2027, reconcile proceeds, the 80% redemption rule, cash versus share settlement, and remaining operating liquidity.
The cheapest falsification test is the Nov. 19 filing and share-count update: determine whether the exchange closed, how many shares were issued, and whether sales under the new agreement were reported. A successful financing does not by itself prove the business is viable; a failed short thesis does not prove it.
The Payoff
This is a 20-session sensitivity through Dec. 14, 2026, from the Nov. 13 3:10:46 p.m. ET reference of $1.86. It uses the $1.815 same-session low, the reference, and the $2.67 prior close. These are historical price anchors, not fair value, trading targets, or bounds. The $2.67 marker is a 43.5% adverse stress for a short; further upside is possible.
The 15% / 55% / 30% weights are subjective and low-confidence, not observed frequencies. The 15% top case is a further fade to the session low; 55% is stabilization while financing and flight milestones remain unresolved; 30% is a partial retrace to the prior close, reflecting the 40.17% reported short float and the possibility that financing extends runway. The short-interest reading is stale and does not establish the rebound probability.
Price Target and Probability Map
| Scenario | Probability | Target / level | Short return from $1.86 | Horizon | Conditions | Evidence quality |
|---|---|---|---|---|---|---|
| Top case | 15% | $1.815 | +2.4% | Through Dec. 14, 2026 | Financing fears persist and the price retests the Nov. 13 low. | Low |
| Base case | 55% | $1.86 | 0.0% | Through Dec. 14, 2026 | The sale agreement and note exchange are unresolved; price stabilizes near the reference. | Low |
| Bottom case | 30% | $2.67 | -43.5% | Through Dec. 14, 2026 | The funding path reduces near-term cash risk and a crowded short partially covers; the prior close is not a ceiling. | Low |
| Invalidation | n/a | No fixed price stop | Rebuild if the new funding and test schedule materially reduce risk; do not treat a lower quote as confirmation. | Any time | Verify filed proceeds, share count, debt settlement, cash, and flight-test results. | Medium |
| Payoff check | Result |
|---|---|
| Probability-weighted expected price | $2.10 |
| Probability-weighted gross short return | -12.7% before borrow, fees, slippage, and carrying costs |
| Current market level and timestamp | $1.86, Nov. 13, 2026, 3:10:46 p.m. ET; regular-session finance-feed snapshot |
| Primary instrument | SPCE common stock, screening only |
| 10/5 favorable base move | 0.0%; the base case is flat |
| 10/5 credible adverse move | +43.5% to the $2.67 prior close; further upside is possible |
| 10/5 measurement basis | Reference-only; no verified executable entry |
| 10/5 status | Reject |
| Gross base reward/adverse ratio | 0.0:1; the base has no positive reward |
| Confidence | Low; price anchors, subjective weights, and stale positioning data |
The Kill Shot
The strongest counterparty view is that new financing can extend the runway. A potential $250M gross sale facility, a reduction in 2027 cash obligations through an equity exchange, $153M of unrestricted cash and securities at Sept. 30, and an expected January glide flight could materially extend the path to commercial operations. The 10-Q’s substantial-doubt conclusion was filed before the Nov. 12–13 financing actions. More than 100 astronauts have begun preparation, and the company opened a limited booking tranche at $850,000 per seat. Those are not current flight revenue, but a successful test or sales at better prices could trigger a sharp re-rating and short-covering.
The load-bearing short assumption is that financing will arrive only through heavy dilution while flight milestones slip. The Nov. 13 note exchange reduces debt and a future cash payment; it is not fresh cash, but it also avoids paying $12.5M principal in cash. The assumed dilution path can fail if shares are issued at higher prices, the exchange closes at a higher VWAP, or customer receipts arrive before the next funding need.
What Could Go Wrong
The short can lose through a successful glide flight, an open-market sale that funds the operating plan, higher seat bookings, a debt amendment that improves flexibility, or a squeeze of the crowded reported short position. The prior close is not an upper bound. The share price can gap on flight or financing news, halt, or move through any stop. Locate, borrow fees, recall terms, spread, depth, and exit capacity are unverified.
What Would Prove This Wrong
Rebuild the thesis if the note exchange closes on or near the stated terms, actual sale proceeds cover planned operations without rapidly exhausting the share count, and the January glide-flight test proceeds on schedule. Any stock issuance, sale of assets, change to restricted cash, or revised debt timetable requires a fresh denominator and liquidity bridge. Do not treat an open-market sale agreement, a successful test, or a lower quote as an automatic trade trigger.
Risk Audit
| Risk | Evidence | Effect on decision |
|---|---|---|
| Runway | Sept. 30 unrestricted cash and securities were about $153M; Q3 FCF was -$99.1M and Q4 FCF guidance is -$80M to -$90M. | Supports funding risk but does not establish a 10% base decline from $1.86. |
| Restricted cash | $31.3M is separately restricted and mainly relates to future-astronaut deposits. | Do not count it as general operating cash. |
| Dilution | New sale capacity is $250M gross; a full sale at the reference price would equal roughly 89% of Nov. 5 shares. | Material if used, but no sales pace or price is disclosed. |
| Debt settlement | $12.5M 2027-note exchange is expected to close Nov. 19; share count depends on future VWAPs. | Helps cash obligations while adding an unknown number of shares. |
| Crowding | 40.17% of provider float short at Oct. 30 settlement; observation predates the gap. | A rebound can squeeze; current positioning is unknown. |
| Flight schedule | First glide flight expected January and first commercial flight early Q2 2027, both issuer targets. | Successful milestones can sharply change sentiment; delay risk remains. |
| Execution | No current locate, borrow cost, recall terms, spread, depth, or exit capacity. | Keep entry null and execution disabled. |
Best Trade Strategy
No trade. The reference-only base is flat, the observed low offers only 2.4% further downside, and the prior close is a 43.5% adverse rise. The probability-weighted short return is negative before costs. Revisit only with current financing, share-count, and flight-test evidence that supports a 10% base decline, a credible adverse path no worse than 5%, at least 2:1 gross reward to adverse risk, positive value after costs, and verified locate, borrow, spread, depth, and exit capacity. Do not use options, leverage, margin, market orders, or price-floor logic.
Sources
- SPCE Q3 2026 Form 10-Q, SEC
- SPCE Q3 2026 results and business update, SEC Exhibit 99.1
- SPCE Nov. 12 2026 open-market sale agreement and note-exchange plan, SEC Form 8-K
- SPCE Nov. 13 2026 note exchange and First Lien indenture amendment, SEC Form 8-K
- SPCE 3:10 p.m. ET quote, finance feed
- SPCE Nov. 12 close reference, ChartExchange
- SPCE Nov. 12 close and FINRA short-interest settlement table, Oct. 30, ChartExchange
- SPCE historical prices, Yahoo Finance
- CDNL Q3 2026 results, SEC Exhibit 99.1
- CDNL Q3 2026 Form 10-Q, SEC
- CDNL 3:10 p.m. ET quote, finance feed
- CDNL FINRA short-interest settlement table, Oct. 30, ChartExchange
- HRTX Q3 2026 results, issuer release
- CorMedix–Heron proposed asset sale, issuer release
- CorMedix Form 8-K and asset purchase agreement, SEC
- HRTX 3:07 p.m. ET quote, finance feed
- HRTX FINRA short-interest settlement table, Oct. 30, ChartExchange
- SPY 3:10 p.m. ET quote, finance feed
- July 2026 MVIS screen that included SPCE as a candidate
- Immediately prior KLC Q3 short screen, excluded from this run
Research Quality Scorecard
| Criterion | Score | Evidence-based reason |
|---|---|---|
| Market disagreement | 4/5 | New financing capacity and debt settlement conflict with a sharp price gap and a filed going-concern warning, but no independent equity value is available. |
| Evidence base | 5/5 | Fresh SEC 10-Q and two 8-Ks, issuer release, timestamped quote, and settlement-dated short interest. |
| Positioning and flows | 2/5 | 40.17% reported short float is material but dated Oct. 30; current lending and covering are unknown. |
| Catalyst path | 4/5 | Nov. 17–19 exchange steps and January test target are observable but conditional. |
| Payoff architecture | 2/5 | The price-only map has no positive base reward and an adverse rebound above 5%. |
| Invalidation discipline | 4/5 | Sale-agreement use, exchange shares, unrestricted cash, and flight milestones are monitorable. |
| Differentiated insight | 4/5 | Separates authorization from cash received and shows the scale of a full sale at the reference price. |
| Client value | 5/5 | Explains why cash stress and financing capacity can coexist, and why neither establishes an executable short. |
| Total | 30/40 | Reject / no-trade screen; failed 10/5 economics take precedence. |
Bottom Line
SPCE’s cash burn and going-concern warning support the bear case, but the new $250M gross sale capacity and $12.5M stock-settled note exchange could extend the runway. At $1.86, the scenario base is flat, the session low is only 2.4% lower, and a return to the prior close is a 43.5% adverse move. The reported short float is high and stale, and further upside is not bounded. Reject / no trade.
AI Illustration Prompt
Create a restrained aerospace-finance research illustration: a single next-generation spaceplane in a hangar above a compact funding bridge labeled “Q3 FCF -$99M”, “Unrestricted cash + securities $153M”, “Restricted cash $31M”, “Sale agreement up to $250M gross, not raised”, and “40.17% short float, Oct. 30”. Add a clearly marked dilution sensitivity: “~134.4M shares only if the full gross facility sold at $1.86”. Do not depict flight success or failure as certain. Use muted navy, warm grey, and one restrained amber accent; add a subtle readable “The Mispricing Desk” watermark.